Methods Evaluated to Detect Asymptomatic Visceral Leishmaniasis
By LabMedica International staff writers Posted on 24 Jul 2019 |
Image: The Multiskan GO microplate spectrophotometer (Photo courtesy of Thermo Fisher Scientific).
Visceral leishmaniasis (VL) is caused by Leishmania infantum [synonymous L. chagasi] in the New World or L. donovani in the Old World, VL can be classified as an anthroponotic or zoonotic disease because it is transmitted between humans and others mammals, such as dogs.
Visceral leishmaniasis in humans presents with fever, anemia, and splenomegaly and can be lethal if not treated. Nevertheless, the majority of L. infantum-infected individuals don’t manifest symptoms, and remain so provided they are not immunosuppressed. Direct and indirect methods are used for diagnosis of VL.
A team of scientists working with the Ribeirão Preto School of Medicine (Ribeirão Preto, Brazil) included in a study of patients with VL before and after treatment, who were hospitalized in the city of Teresina, and volunteers without any symptom of the disease residing in the same city. Sample collections were carried out between August and November 2017. Samples obtained from healthy volunteers residing in the city of Ribeirão Preto, were used as control of non-endemic area. The diagnosis of VL was confirmed by the positivity of amastigote forms in samples of bone marrow aspirate stained by Giemsa, and confirmed by cell culture in NNN medium.
Immunochromatographic tests (IC) were performed using Kalazar Detect Rapid, and the OnSite Leishmania IgG/IgM Combo test. An in-house enzyme-linked immunosorbent assay (ELISA) was performed and read on a Multiskan GO microplate spectrophotometer. DNA extraction was performed using 200 μL of total peripheral blood. IFN-γ-induced protein 10 (IP-10) and monokine induced by IFN-γ (MIG) were quantified in the study in 50 μL of plasma from whole blood soluble Leishmania antigen (SLA)-stimulated or non-SLA-stimulated using the BD Cytometric Bead Array Human Flex Set.
The scientists reported that Kalazar Detect and OnSite detected, respectively, 76% and 64% of patients presenting with active VL; 50% and 57% of patients remained positive in these tests, respectively, after treatment. Of the healthy participants in the study who were living in the endemic area, only 1.7% were positive with both of the IC tests. On the other hand, reactivity in ELISA tests revealed that 13% of these individuals presented asymptomatic infections; among VL patients, 84% presenting with active disease were reactive in ELISA and after treatment, 55.5% were seropositive. L. infantum DNA was present in the blood of 37.9% of infected individuals living in the endemic area, while IP-10 and MIG biomarkers were detected in 26.7% of them.
The authors concluded that the association of different techniques can detect asymptomatic infections, however, more investigation is necessary to develop ideal biomarkers that are simple to use in the clinic and in field studies in areas endemic for visceral leishmaniasis. The study was published on July 1, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ribeirão Preto School of Medicine
Visceral leishmaniasis in humans presents with fever, anemia, and splenomegaly and can be lethal if not treated. Nevertheless, the majority of L. infantum-infected individuals don’t manifest symptoms, and remain so provided they are not immunosuppressed. Direct and indirect methods are used for diagnosis of VL.
A team of scientists working with the Ribeirão Preto School of Medicine (Ribeirão Preto, Brazil) included in a study of patients with VL before and after treatment, who were hospitalized in the city of Teresina, and volunteers without any symptom of the disease residing in the same city. Sample collections were carried out between August and November 2017. Samples obtained from healthy volunteers residing in the city of Ribeirão Preto, were used as control of non-endemic area. The diagnosis of VL was confirmed by the positivity of amastigote forms in samples of bone marrow aspirate stained by Giemsa, and confirmed by cell culture in NNN medium.
Immunochromatographic tests (IC) were performed using Kalazar Detect Rapid, and the OnSite Leishmania IgG/IgM Combo test. An in-house enzyme-linked immunosorbent assay (ELISA) was performed and read on a Multiskan GO microplate spectrophotometer. DNA extraction was performed using 200 μL of total peripheral blood. IFN-γ-induced protein 10 (IP-10) and monokine induced by IFN-γ (MIG) were quantified in the study in 50 μL of plasma from whole blood soluble Leishmania antigen (SLA)-stimulated or non-SLA-stimulated using the BD Cytometric Bead Array Human Flex Set.
The scientists reported that Kalazar Detect and OnSite detected, respectively, 76% and 64% of patients presenting with active VL; 50% and 57% of patients remained positive in these tests, respectively, after treatment. Of the healthy participants in the study who were living in the endemic area, only 1.7% were positive with both of the IC tests. On the other hand, reactivity in ELISA tests revealed that 13% of these individuals presented asymptomatic infections; among VL patients, 84% presenting with active disease were reactive in ELISA and after treatment, 55.5% were seropositive. L. infantum DNA was present in the blood of 37.9% of infected individuals living in the endemic area, while IP-10 and MIG biomarkers were detected in 26.7% of them.
The authors concluded that the association of different techniques can detect asymptomatic infections, however, more investigation is necessary to develop ideal biomarkers that are simple to use in the clinic and in field studies in areas endemic for visceral leishmaniasis. The study was published on July 1, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ribeirão Preto School of Medicine
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms